James G. Christensen

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

Aileen McHarg, Jing Yuan, Peter K. Vogt, 2011, Molecular Cancer Therapeutics.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

Andrew L. Kung, Jonathan D. Licht, Alex Kentsis, 2012, Nature Medicine.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Shinji Yamazaki, J. Christensen, B. Mroczkowski, 2007, Molecular Cancer Therapeutics.

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers

Mary E. Winn, L. Turner, J. Christensen, 2016, Oncotarget.

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Paul A. Rejto, Jing Yuan, Keith A. Ching, 2012, Molecular Cancer Therapeutics.

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Shinji Yamazaki, Tod Smeal, J. Christensen, 2012, Molecular Cancer Therapeutics.